Teva announced the launch of Risedronate Sodium Delayed-Release Tablets, the generic version of Warner Chilcott’s Atelvia. Atelvia is a bisphosphonate indicated for the treatment of postmenopausal osteoporosis.

Risedronate has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent. At the cellular level, risedronate inhibits osteoclasts. Risedronate treatment reduces bone turnover (activation frequency, that is, the rate at which bone remodeling sites are activated) and bone resorption at remodeling sites.

RELATED: Osteoporosis Treatments

Risedronate Sodium Delayed-Release Tablets are available in a 35mg strength in 4-count blister packs.

For more information call (888) 838-2872 or visit